Research on Innovative Traditional Chinese Medicine Diagnosis and Treatment Technologies for Diab… (NCT07459946) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Research on Innovative Traditional Chinese Medicine Diagnosis and Treatment Technologies for Diabetic Nephropathy Driven by Multi-Omics and Artificial Intelligence
198 participantsStarted 2026-03-12
Plain-language summary
With the help of the 'Traditional Chinese Medicine Specialty Alliance Platform-Multicenter RCT Clinical Research Database,' this platform can be used to conduct scientific research on various aspects of DKD, such as disease prediction, treatment effectiveness evaluation, and recurrence rate analysis, providing effective means to improve DKD remission rates, delay disease progression, and enhance patients' quality of life. By selecting the Jiade Yishen Xiaozheng Qufang formula and conducting multicenter, prospective, double-blind RCT studies, its clinical value in improving DKD remission rates can be verified. With the support of scientific research, DKD treatment strategies can be optimized, therapeutic efficacy improved, recurrence rates reduced, and disease progression delayed, thereby enhancing patients' quality of life.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Meets the clinical diagnostic criteria for diabetic nephropathy;
✓. Aged 18-75 years, any gender;
✓. eGFR \>45 ml/min/1.73m²;
✓. 24-hour urine protein \<2.0 g/day;
✓. Exhibits Traditional Chinese Medicine patterns of deficiency, stasis, or rheumatic symptoms;
✓. Willing to participate in the study, able to attend regular follow-ups, and provide informed consent;
✓. Has maintained a stable basic treatment plan (including hypoglycemic, antihypertensive, and lipid-lowering therapies) for ≥1 month prior to enrollment; during the first 3 months after enrollment, ARB, finerenone, and SGLT2 inhibitor therapies should generally not be adjusted.
Exclusion criteria
✕. Acute kidney injury or renal function impairment caused by other reasons (recent rapid decline in renal function, or kidney damage caused by drugs, infections, etc.);
✕
What they're measuring
1
UACR/UAER/24-hour urinary protein returns to normal or decreases by 50% compared with before.
Timeframe: Western medical efficacy evaluation will be conducted at weeks 0, 4, 8, 12, 16, 20, and 24